340B Drug Pricing Program
Following the recent district court decision to remand to the Department of Health and Human Services the question of how to repay 340B hospitals for funds unlawfully withheld for five years,
AHA requests the opportunity to meet with HHS now that the district court in American Hospital Association v. Becerra has remanded the question of how to repay 340B hospitals to the Department of Health and Human Services.
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled today in Sanofi-Aventis U.S. v. HHS et al. Cases raising similar legal questions are pending…
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled in Sanofi-Aventis U.S. v. HHS et al. Cases raising similar legal questions are pending in the…
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.S. Court of Appeals for the 3rd Circuit ruled in Sanofi-Aventis U.S. v. HHS et al.
January 27, 2023
Emeka Egwim, PharmD, RPh LCDR
U.S. Public Health Service Director
Office of Pharmacy Affairs
Health Resources and Services Administration 5600 Fishers Lane, 08W05A
Rockville, MD 20857
RE: HRSA 340B Drug Pricing Program; Administrative Dispute Resolution Proposed Rule, HHS Docket…
AHA 340B Hospital Members Urged to Submit Comments on HRSA’s Proposed Rule on the 340B Administrative Dispute Resolution Process, Model Comment Letter Available
Memorandum Opinion: Granting in Part, Denying In Part Plaintiffs Motion to Hold Unlawful and Remedy Defendants’ Past Underpayments of 340b Drugs
As drug prices continue to rise, the 340B drug pricing program continues to help hospitals expand access to comprehensive health services, including lifesaving prescription drugs for those in need who may not be able to afford them, writes AHA President and CEO Rick Pollack in the Wall Street…
The U.S. District Court for the District of Columbia today decided to allow the Department of Health and Human Services to propose an appropriate remedy for its past underpayments to hospitals participating in the 340B drug pricing program